A new drug is able to prevent thrombosis effectively
Oral anticoagulants are the most basic medicines for the treatment and prevention of arterial and venous thromboembolism. In case of insufficient use of anticoagulants in patients with atrial fibrillation, and incorrect doses, the risk of bleeding increases. Scientists believe that the new candidate Milvexian will be a worthy alternative to existing drugs. Milvexian is an oral anticoagulant, a novel factor Xia inhibitor that stands out due to its low bleeding rate.
A phase 2 AXIOMATIC-TKR study on Milvexian was conducted at McMaster University in Hamilton. The study planned knee arthroplasty, which included 1242 patients. The patients who took milvexian were in one group, and the patients received subcutaneous injections of enoxaparin were in the comparison group. According to the results of the study, it became known that venous thromboembolism occurred in 21% of patients in the comparison group. In the milvexian group, this complication developed with different frequency. Due to the dosage of the drug, the parameters in patients had a lower percentage. Also, major or clinically minor bleeding episodes occurred in 1% of patients, who received milvexian and 2% of those, who received enoxaparin.